Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOSTER-024 long-term follow-up of gE/AS01B herpes zoster vaccine
NL-OMON36034Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Cell-mediated immunity and Humoral immunity. Started Apr 2011; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON36034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36034.